Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety ...
Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...
Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
Myocardial ischemia is a drop in blood flow to the heart. Myocardial infarction, or heart attack, occurs when death or damage occurs in the muscle tissue of the heart due to low blood supply. The ...
Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...
Presenter: Stuart J. Connolly, MD, McMaster University (Hamilton, Ontario, CANADA) and Stefan H. Hohnloser, MD, J.W. Goethe University (Frankfurt, Germany) Large randomized clinical trials have ...
The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results